LY 3209590

Drug Profile

LY 3209590

Alternative Names: LY-3209590

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 18 Oct 2017 Eli Lilly completes a phase I trial in Type-2 diabetes mellitus in Germany (SC) (NCT02942914)
  • 01 Dec 2016 Phase-I clinical trials in Type-2 diabetes mellitus in Germany (SC) (NCT02942914)
  • 27 Oct 2016 Preclinical trials in Type-2 diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top